In a small household in Elizabethton, Tennessee, politics has long been a source of lively disagreement. Amye Joseph identifies as a Republican, while her husband, Charlie, is a Democrat. The couple has been married for 35 years, and Amye describes the current era of American political polarization as an "interesting time" to share a home across party lines. Yet despite their differing views on many issues, the two have found something they can agree on: a deep frustration with pharmacy benefit managers, the little-understood companies that sit between drug manufacturers, insurers, and patients.
Pharmacy benefit managers, commonly known as PBMs, were originally created to serve as administrators of prescription drug plans. Their stated purpose was to manage complex medication lists, negotiate with drugmakers on behalf of insurers and employers, and ultimately hold down costs for the people who pay for healthcare. In theory, the middleman role would create savings by leveraging large purchasing power. In practice, however, PBMs have increasingly become the target of bipartisan anger, accused of absorbing profits while employers, government programs, and patients shoulder the financial burden.
That anger is now translating into a rare phenomenon in American politics: Democrats and Republicans, patients and politicians alike, seem united in their disdain for these healthcare conglomerates. The shared frustration spans the ideological spectrum, cutting through the partisan gridlock that typically defines debates over healthcare policy in Washington, D.C. Instead of arguing over the broader direction of the healthcare system, lawmakers from both parties are finding common ground in their criticism of PBMs, an issue that resonates with voters who feel squeezed by rising medical expenses.
The Josephs' specific grievance centers on CVS Health, a corporate giant that reported $400 billion in revenue last year. CVS Health is not just one company but a sprawling conglomerate that operates several major pieces of the American healthcare system: Aetna, a prominent health insurer; CVS Caremark, one of the nation's dominant PBMs; and CVS Pharmacy, the largest retail pharmacy chain in the country. This vertical integration means the same corporation can influence what drugs patients are offered, how much they cost, and where they can be purchased, a concentration of power that critics say creates inherent conflicts of interest.
Amye Joseph did not hold back when describing her feelings about the company. "We hate CVS," she said bluntly. She pointed to a lack of face-to-face interaction with pharmacists, prices that appear to increase without clear explanation, and pressure from the couple's CVS Caremark drug plan to fill prescriptions at CVS stores rather than at their preferred local pharmacy. In her view, the company functions less as a neutral intermediary and more as a mechanism for extracting money. "They're not even a middleman," she said. "They're a money grab for CVS."
The dissatisfaction expressed by the Josephs reflects a broader pattern of consumer frustration with the American healthcare system. Patients across the country report similar experiences: shrinking access to familiar pharmacists, opaque pricing structures, and limited choices about where to fill prescriptions. These complaints have begun to draw attention from state lawmakers who see an opportunity to act where federal consensus has been elusive.
Tennessee and Arkansas have emerged as early movers in the effort to regulate PBMs. The two states are advancing rules and oversight aimed at curbing some of the practices that critics say drive up costs and limit patient options. While the specifics of each state's approach may differ, the underlying motivation is the same: a belief that PBM business practices deserve greater scrutiny and that state-level action can provide relief to consumers and local pharmacies that feel squeezed by the current arrangement.
The push for regulation comes amid a backdrop of significant disruption in the pharmacy industry. Large chains are facing their own financial pressures. Walgreens, for instance, announced plans to close 1,200 stores, a sign of deep challenges in the retail pharmacy sector. Meanwhile, CVS recently laid off thousands of workers as part of an effort to cut costs. These developments suggest that the healthcare landscape is shifting, and not necessarily in ways that benefit patients or the workers who serve them.
PBMs argue that they play a necessary role in the complex drug supply chain, negotiating discounts and managing formularies to keep costs manageable. But their critics contend that the savings they negotiate often do not reach the people who need them most. Instead, the companies are accused of pocketing rebates and fees, while patients face rising out-of-pocket expenses at the pharmacy counter. This disconnect between promised cost savings and real-world sticker shock has fueled the bipartisan backlash.
The political implications of this issue are significant. Healthcare costs consistently rank among voters' top concerns, and few topics generate as much cross-party agreement as frustration with perceived corporate greed in the medical industry. For Democrats, taking on PBMs fits naturally into a broader critique of profit-driven healthcare. For Republicans, the issue aligns with concerns about corporate power, transparency, and the need for market competition to function fairly. The result is a rare convergence of political interests that could produce meaningful legislative action.
Advocates for reform argue that without stronger oversight, PBMs will continue to consolidate power and extract profits at the expense of patients and independent pharmacies. They point to the vertical integration exemplified by CVS Health as evidence that the current system lacks sufficient checks and balances. When one company controls insurance, pharmacy benefits, and retail pharmacies, the incentive to prioritize patient welfare over shareholder returns may be weakened.
The story of Amye and Charlie Joseph illustrates how deeply these concerns can cut across party lines. Their marriage has survived 35 years and a politically polarized era, and their shared exasperation with the healthcare status quo has given them common ground. Their experience suggests that the PBM debate is not simply a policy dispute among elites in Washington but a kitchen-table issue that affects families regardless of how they vote.
As state legislatures in Tennessee, Arkansas, and potentially elsewhere consider new rules, the pressure on PBMs is likely to intensify. Whether this bipartisan momentum will lead to meaningful change at the federal level remains uncertain, but the current dynamic shows that some healthcare issues can transcend party affiliation. For now, the unlikely alliance of Republicans and Democrats against pharmacy benefit managers stands as a notable exception to the gridlock that defines so much of modern American politics.
(0)